{"nctId":"NCT00506389","briefTitle":"A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)","startDateStruct":{"date":"2007-06-06","type":"ACTUAL"},"conditions":["Insomnia"],"count":419,"armGroups":[{"label":"Esmirtazapine 3.0 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Esmirtazapine"]},{"label":"Esmirtazapine 4.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Esmirtazapine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Esmirtazapine","otherNames":["ORG 50081"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented diagnosis of chronic primary insomnia\n\nExclusion Criteria:\n\n* Other sleep disorder such as sleep apnea, restless leg syndrome, narcolepsy, sleep/wake rhythm disorders\n* Has significant medical or psychiatric illness as causing the sleep disorder\n* Diagnosed with major depressive disorder\n* Substance abuse within the past year\n* Night worker or work on rotating shifts\n* Has had serious head injury, stroke, epilepsy\n* Has a history of bipolar disorder or family (immediate family) history of suicide\n* Smokes more than 15 cigarettes per day and cannot abstain from smoking during the night or in the sleep laboratory\n* Drinks beverages containing more than 500 mg caffeine per day","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Average Wake Time After Sleep Onset (WASO) During the In-Treatment Period","description":"WASO was defined as the total objective time awake after the onset of persistent sleep until the end of the 8-hour sleep cycle period as measured by polysomnography (PSG). WASO was calculated as the mean of Nights 1, 15, and 36.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.6","spread":"25.7"},{"groupId":"OG001","value":"45.5","spread":"26.5"},{"groupId":"OG002","value":"76.1","spread":"46.0"}]}]}]},{"type":"SECONDARY","title":"Average Latency to Persistent Sleep (LPS) During the In-Treatment Period","description":"LPS was defined as the time in minutes from lights out to the first 20 consecutive epochs scored as sleep as measured by PSG. LPS was calculated as the mean of Nights 1, 15, and 36.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.7","spread":"28.4"},{"groupId":"OG001","value":"26.1","spread":"23.0"},{"groupId":"OG002","value":"40.5","spread":"27.3"}]}]}]},{"type":"SECONDARY","title":"Average Subjective Total Sleep Time (TST) During the In-Treatment Period","description":"TST was defined as the total amount of time in minutes that was actually spent sleeping the previous night as recorded daily in the participant's sleep diary. TST values over the 6 week In-Treatment Period were averaged for each participant, and average TST was then reported by treatment arm. For participants with missing data, the average of the nights for which TST data were available was used in the analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"384.6","spread":"63.6"},{"groupId":"OG001","value":"384.6","spread":"66.2"},{"groupId":"OG002","value":"351.6","spread":"57.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":139},"commonTop":["Somnolence","Headache"]}}}